Advancing Biomarker-Driven Strategies in NSCLC: Exploring the Emerging Role of QCS and TROP2 NMR - Episode 1
Advancing Biomarker Assessment for TROP2: Moving Beyond Conventional IHC
Panelists discuss the evolving role of advanced biomarker tools like quantitative continuous scoring (QCS) and normalized membrane ratio (NMR) in non–small cell lung cancer (NSCLC), highlighting their potential to overcome limitations of traditional TROP2 assessment, improve prediction of antibody-drug conjugate (ADC) efficacy, and enhance patient selection through more precise and functional tumor profiling.
Biomarker-driven strategies continue to reshape the management of NSCLC, with increasing attention given to refining diagnostic tools that can better inform treatment decisions. In this context, TROP2 and novel approaches like QCS and NMR are gaining traction. These tools aim to go beyond traditional biomarker assessments by quantifying expression levels more precisely and offering a more functional understanding of target engagement and drug delivery potential. Such refinement is especially important when working with ADCs, which rely not only on target presence but also on effective internalization into tumor cells.
One of the major challenges in evaluating TROP2 expression is that surface-level presence alone may not predict therapeutic response. Unlike some targets where expression levels directly correlate with treatment benefit, TROP2-targeted ADCs, such as those using topoisomerase inhibitors, require efficient internalization for efficacy. Simply detecting protein expression on the membrane may not be adequate; instead, methods that assess dynamic processes—such as NMR—are being explored to determine how much of the targeted payload is likely to reach the intracellular environment. This could potentially improve patient selection and ensure that therapies are matched more precisely to biological activity within the tumor.
Looking ahead, the integration of advanced scoring metrics like QCS and NMR into routine pathology could help overcome the limitations of binary biomarker assessments. These tools provide a continuum of expression data that may better reflect underlying tumor biology and improve predictive accuracy. As the field of precision oncology evolves, incorporating these nuanced methods could lead to more effective therapeutic stratification and optimized use of targeted agents. Continued research and validation in clinical trials will be crucial for determining how these technologies can be standardized and implemented in daily practice.
Related Content:
